| Literature DB >> 35016813 |
Amar Doshi1, Keyur B Shah2, Sean Agbor-Enoh3, Zackary Tushak1, Victoria Garcia1, Hyesik Kong4, Moon K Jang4, Steven Hsu5, Erika D Feller6, Maria E Rodrigo7, Samer S Najjar7, Ilker Tunc8, Yanqin Yang9, Seiyon Lee10, Michael A Solomon11, Gerald Berry12, Charles Marboe13, Palak Shah14, Hannah A Valantine15.
Abstract
Black patients suffer higher rates of antibody-mediated rejection and have worse long-term graft survival after heart transplantation. Donor-derived cell free DNA (ddcfDNA) is released into the blood following allograft injury. This study analyzed %ddcfDNA in 63 heart transplant recipients categorized by Black and non-Black race, during the first 200 days after transplant. Immediately after transplant, %ddcfDNA was higher for Black patients (mean [SE]: 8.3% [1.3%] vs 3.2% [1.2%], p = 0.001). In the first week post-transplant, the rate of decay in %ddcfDNA was similar (0.7% [0.68] vs 0.7% [0.11], p = 0.78), and values declined in both groups to a comparable plateau at 7 days post-transplant (0.46% [0.03] vs 0.45% [0.04], p = 0.78). The proportion of Black patients experiencing AMR was higher than non-Black patients (21% vs 9% [hazard ratio of 2.61 [95% confidence interval: 0.651-10.43], p = 0.18). Black patients were more likely to receive a race mismatched organ than non-Black patients (69% vs 35%, p = 0.01), which may explain the higher levels of early allograft injury.Entities:
Keywords: acute rejection; biomarker; cardiac transplantation; cell-free DNA; graft injury
Mesh:
Year: 2021 PMID: 35016813 DOI: 10.1016/j.healun.2021.12.006
Source DB: PubMed Journal: J Heart Lung Transplant ISSN: 1053-2498 Impact factor: 13.569